Evidence map›Paper›PMID 8709277›Full record

ArticleJournal of virology1996

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

V Litwin, K A Nagashima, A M Ryder, C H Chang, J M Carver, W C Olson, M Alizon, K W Hasel, P J Maddon, G P Allaway

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

V LitwinProgenics Pharmaceuticals, Inc., Tarrytown, New York 10591, USA.
K A Nagashima
A M Ryder
C H Chang
J M Carver
W C Olson
M Alizon
K W Hasel
P J Maddon
G P Allaway
Progenics Pharmaceuticals (United States) · US

Funding

RAPID FLUOROMETRIC ASSAY OF HIV-INDUCED CELL FUSIONR43AI032813 · NIAID · PROGENICS PHARMACEUTICALS, INC. · PI MADDON, PAUL J · 1992 to 1992
–
RAPID FLUOROMETRIC ASSAY OF HIV-INDUCED CELL FUSIONR44AI032813 · NIAID · PROGENICS PHARMACEUTICALS, INC. · PI MADDON, PAUL J · 1994 to 1995
–
NIAID NIH HHS AI32813
6 · The paper itself

Abstract

Previous studies of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein-mediated membrane fusion have focused on laboratory-adapted T-lymphotropic strains of the virus. The goal of this study was to characterize membrane fusion mediated by a primary HIV-1 isolate in comparison with a laboratory-adapted strain. To this end, a new fusion assay was developed on the basis of the principle of resonance energy transfer, using HeLa cells stably transfected with gp120/gp41 from the T-lymphotropic isolate HIV-1LA1 or the macrophage-tropic primary isolate HIV-1JR-FL. These cells fused with CD4+ target cell lines with a tropism mirroring that of infection by the two viruses. Of particular note, HeLa cells expressing HIV-1JR-FL gp120/gp41 fused only with PM1 cells, a clonal derivative of HUT 78, and not with other T-cell or macrophage cell lines. These results demonstrate that the envelope glycoproteins of these strains play a major role in mediating viral tropism. Despite significant differences exhibited by HIV-1JR-FL and HIV-1LAI in terms of tropism and sensitivity to neutralization by CD4-based proteins, the present study found that membrane fusion mediated by the envelope glycoproteins of these viruses had remarkably similar properties. In particular, the degree and kinetics of membrane fusion were similar, fusion occurred at neutral pH and was dependent on the presence of divalent cations. Inhibition of HIV-1JR-FL envelope glycoprotein-mediated membrane fusion by soluble CD4 and CD4-IgG2 occurred at concentrations similar to those required to neutralize this virus. Interestingly, higher concentrations of these agents were required to inhibit HIV-1LAI envelope glycoprotein-mediated membrane fusion, in contrast to the greater sensitivity of HIV-1LAI virions to neutralization by soluble CD4 and CD4-IgG2. This finding suggests that the mechanisms of fusion inhibition and neutralization of HIV-1 are distinct.

Indexed as

Membrane FusionAntigens, CDCD4 AntigensCell LineEnergy TransferFlow CytometryGene Products, envHeLa CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HumansImmunoglobulin GMacrophagesRecombinant Fusion ProteinsTransfectionAntigens, CDCD4 AntigensGene Products, envHIV Envelope Protein gp120HIV Envelope Protein gp41Immunoglobulin GRecombinant Fusion Proteins

Identifiers

PMID8709277
PMCPMC190675
OpenAlexW2171411599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.